BRIEF—ReNAgade Therapeutics launches with over $300 million in Series A financing

ReNAgade Therapeutics, a Cambridge, USA-based company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.

Founded by MPM BioImpact, ReNAgade is led by chairman and chief executive Amit Munshi, an industry veteran with more than 30 years of experience leading biotech companies and most recently the CEO of Arena Pharmaceuticals – which he sold off to Pfizer for $6.7 billion, with support from a world-class executive and scientific team.

ReNAgade has built a comprehensive and complementary platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system.

ReNAgade aims to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market.

The company has an established joint venture with Orna Therapeutics, combining ReNAgade’s delivery platform with Orna’s circular RNA technology.

Subsequently, Orna has entered into a collaboration with Merck & Co, which includes technologies developed under the Orna/ReNAgade JV.